Proteomic analyses of regulating factors of neovascular ocular inflammation and retinal edema

Proteomic analyses of regulating factors of neovascular ocular inflammation and retinal edema - Proteome of neovascular ocular inflammation and retinal edema

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003854

Enrollment

600

Registered

2010-07-01

Start date

2008-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy, Retinal vein occlusion, Retinal artery occlusion, Age-related macular degeneration, Neovascular maculopathy, Neovascular glaucoma, Macula edema, Uveitis, Glaucoma, Cataract

Interventions

Anti-VEGF antibody treatment (Ranibizmab or Bevacizumab) Anti-VEGF antibody treatment (Ranibizmab or Bevacizumab), followed by photodynamic therapy No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eyes which require anti-VEGF therapy or surgical intervention

Exclusion criteria

Exclusion criteria: Eyes with laser coagulation and photodynamic therapy within the past 5 months, and intraocular surgery including cataract surgery in the study eye within the past 5 months.

Design outcomes

Primary

Measure	Time frame
Inflammatory cytokine levels and proteome of aqueous humor of patients before and after treatment (including 1 month after treatment), and clinical parameters including visual acuity, findings from retinal tomography and angiography.	—

Countries

Japan

Contacts

Public ContactDai Miyazaki

Faculty of Medicine, Tottori University Division of Ophthalmology and Visual Science

dm@grape.med.tottori-u.ac.jp+81-859-38-6617

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026